12/20
05:47 am
rcus
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week [Yahoo! Finance]
Medium
Report
Shareholders in Arcus Biosciences (NYSE:RCUS) have lost 65%, as stock drops 9.9% this past week [Yahoo! Finance]
12/19
04:17 pm
rcus
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/19
04:05 pm
rcus
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
12/10
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Medium
Report
Arcus Biosciences Announces New Employment Inducement Grants
12/9
01:07 pm
rcus
Adenosine Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Adenosine Antagonists Therapeutics | DelveInsight [Yahoo! Finance]
Low
Report
Adenosine Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Adenosine Antagonists Therapeutics | DelveInsight [Yahoo! Finance]
12/3
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Medium
Report
Arcus Biosciences Announces New Employment Inducement Grants
11/19
04:19 pm
rcus
Arcus Biosciences to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
Arcus Biosciences to Participate in Two Upcoming Investor Conferences [Yahoo! Finance]
11/19
04:05 pm
rcus
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
Low
Report
Arcus Biosciences to Participate in Two Upcoming Investor Conferences
11/12
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Low
Report
Arcus Biosciences Announces New Employment Inducement Grants
11/9
10:22 am
rcus
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report [Yahoo! Finance]
Low
Report
Analysts Have Made A Financial Statement On Arcus Biosciences, Inc.'s (NYSE:RCUS) Third-Quarter Report [Yahoo! Finance]
11/7
02:31 am
rcus
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
Neutral
Report
Arcus Biosciences Inc (RCUS) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... [Yahoo! Finance]
11/6
04:30 pm
rcus
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update [Yahoo! Finance]
Low
Report
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update [Yahoo! Finance]
11/6
04:22 pm
rcus
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
Medium
Report
Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update
11/6
08:07 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Low
Report
Arcus Biosciences, Inc. (NYSE: RCUS) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
11/5
09:00 am
rcus
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
Low
Report
Arcus Biosciences Announces that Domvanalimab Plus Zimberelimab Improved Overall Survival in ARC-10, a Randomized Study in Patients with PD-L1-High Non-Small Cell Lung Cancer
11/5
07:56 am
rcus
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings [Yahoo! Finance]
Low
Report
What To Expect From Arcus Biosciences Inc (RCUS) Q3 2024 Earnings [Yahoo! Finance]
10/30
09:00 am
rcus
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
Low
Report
Arcus Biosciences to Present New Data for Anti-TIGIT Domvanalimab Plus Zimberelimab at the Society for Immunotherapy of Cancer Annual Meeting
10/25
01:44 pm
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) had its price target raised by analysts at Barclays PLC from $25.00 to $29.00. They now have an "overweight" rating on the stock.
Low
Report
Arcus Biosciences, Inc. (NYSE: RCUS) had its price target raised by analysts at Barclays PLC from $25.00 to $29.00. They now have an "overweight" rating on the stock.
10/24
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Medium
Report
Arcus Biosciences Announces New Employment Inducement Grants
10/24
07:30 am
rcus
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
Low
Report
First Clinical Data for Arcus Biosciences’ HIF-2a Inhibitor, Casdatifan, Showed Promising Clinical Activity and Tumor Shrinkage in Patients with Metastatic Kidney Cancer
10/22
04:05 pm
rcus
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
Medium
Report
Arcus Biosciences to Host Conference Call to Discuss Third-Quarter 2024 Financial Results and Pipeline Update
10/21
08:07 am
rcus
Arcus Biosciences, Inc. (NYSE: RCUS) is now covered by analysts at HC Wainwright. They set a "neutral" rating and a $20.00 price target on the stock.
Medium
Report
Arcus Biosciences, Inc. (NYSE: RCUS) is now covered by analysts at HC Wainwright. They set a "neutral" rating and a $20.00 price target on the stock.
10/9
04:35 pm
rcus
Arcus Biosciences Announces New Employment Inducement Grants
Low
Report
Arcus Biosciences Announces New Employment Inducement Grants
10/9
08:39 am
rcus
Arcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share Price [Yahoo! Finance]
Low
Report
Arcus Biosciences, Inc.'s (NYSE:RCUS) Intrinsic Value Is Potentially 30% Above Its Share Price [Yahoo! Finance]
10/9
08:00 am
rcus
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium
Low
Report
Arcus Biosciences to Present First Clinical Data from ARC-20 Study at the 2024 EORTC-NCI-AACR Symposium